SymBio re­ceives li­cens­ing rights from Ea­gle Pharma

BioSpectrum (Asia) - - Company News -

Ea­gle Phar­ma­ceu­ti­cals, Inc. has li­censed to SymBio Phar­ma­ceu­ti­cals Limited rights un­der Ea­gle’s in­tel­lec­tual prop­erty to de­velop, mar­ket and sell Ea­gle’s ben­damus­tine hy­drochlo­ride (ben­damus­tine HCl) ready-to-di­lute (RTD) and rapid in­fu­sion (RI) in­jec­tion prod­ucts in Ja­pan.

SymBio will be re­spon­si­ble for se­cur­ing reg­u­la­tory ap­proval of the RTD and RI in­jec­tion prod­ucts us­ing the li­censed tech­nol­ogy in Ja­pan with a tar­get for ap­proval of a prod­uct in 2020. SymBio cur­rently mar­kets TREAKISYM in Ja­pan, a lyophilized pow­der for­mu­la­tion of ben­damus­tine HCl in­di­cated for chronic lym­pho­cytic leukemia (CLL); re­lapsed or re­frac­tory low-grade Hodgkin’s lym­phoma (NHL); man­tle cell lym­phoma (MCL); and as a first line treat­ment of low-grade NHL and MCL.

Ac­cord­ing to SymBio, 12-month sales ended June 30, 2017 in Ja­pan for TREAKISYM were $52 mil­lion, due to the ap­proval of first line treat­ment for NHL and MCL in De­cem­ber 2016. SymBio has es­ti­mated that sales of TREAKISYM are es­ti­mated to grow to $90 mil­lion in 2018.

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.